Dr. Lyden is the Professor of Physiology & Neuroscience and Neurology at the Zilkha Neurogenetic Institute in the Keck School of Medicine at USC. Dr. Lyden helped lead the pivotal NINDS t-PA for Acute Stroke Trial, the first proven therapy for stroke. He is recognized globally for leadership in stroke therapy, having led large, multi-national trials for NIH and industry. Dr. Lyden is the Principal investigator of the NINDS-sponsored Stroke Preclinical Assessment Network, or SPAN, the first multi-site trial intended to identify candidate treatments likely to succeed in human clinical trials. He is the Chair of the Stroke Council of the American Heart Association/American Stroke Association. Dr. Lyden has been elected a Fellow of the American Academy of Neurology, American Neurology Association, American Heart Association, and the European Stroke Organization. In 2019 he was awarded the prestigious William M. Feinberg Award for Excellence in Clinical Stroke by the American Heart Association. Beginning in 2023 he will lead a 100-center, $20M clinical trial of a new drug for stroke treatment in the NIH funded StrokeNet network.